SCHEMBL1970277

SCHEMBL1970277

COCCOc1cc(NCc2ccccc2)c([N+](=O)[O-])cc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
MEN1 O00255 2/20 0.51
GAA P10253 2/20 0.51
KMT2A Q03164 2/20 0.51
L3MBTL1 Q9Y468 3/20 0.49
CRHBP P24387 1/20 0.49
HTT P42858 1/20 0.49
CRHR2 Q13324 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
AKR1C3 P42330 2/20 0.48
AKR1C2 P52895 2/20 0.48
AKR1C1 Q04828 1/20 0.48
HCAR3 P49019 1/20 0.47
LMNA P02545 1/20 0.46
POLB P06746 2/20 0.46
KCNH2 Q12809 1/20 0.46
ABCB1 P08183 2/20 0.45
ABCC1 P33527 1/20 0.45
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971829 0.88 GAA (0.49) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL2698732 0.80 MAPT (0.58) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL1974278 0.79 L3MBTL1 (0.50) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL9537129 0.78 MAPT (0.60) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL1967409 0.75 RAB9A (0.44) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL6816524 0.74 MAPT (0.59) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL7370622 0.73 MAPT (0.56) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL12100638 0.73 MAPT (0.58) MAPTMEN1GAAKMT2AL3MBTL1
SCHEMBL1436413 0.72 ALDH1A1 (0.49) MAPTGAAL3MBTL1HTTAKR1C3
SCHEMBL6474847 0.72 HTR6 (0.58) MAPTMEN1GAAKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040565-B2 1H-benzimidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2015-05-26 US disclosed
US-20120122930-A1 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-17 US disclosed
EP-2334664-A1 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP disclosed
WO-2010034797-A1 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122930-A1 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, MAP4 MAPT 515/4885MEN1 2458/4885GAA 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.